7342 results for "canc*"

in 19.79 milliseconds.

• Normal sample for patient SA278

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA278

  Dataset EGAD00001009561

• Tumour sample for patient SA533

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA533

  Dataset EGAD00001009517

• Tumour sample for patient SA420

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA420

  Dataset EGAD00001009519

• Tumour sample for patient SA296

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA296

  Dataset EGAD00001009520

• Cancers of Unknow Primary

  genetic data of 14 rigorously selected CUP samples

  Dataset EGAD00001009426

• Single Cell Genome Sequence for DLP+ library A110660A

  Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA610 passage 3 on DLP+ library A110660A

  Dataset EGAD00001009430

• Single Cell Genome Sequence for DLP+ library A96212B

  Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA604 passage 7 on DLP+ library A96212B

  Dataset EGAD00001009476

• Single Cell Genome Sequence for DLP+ library A96213A

  Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA501 passage 6, cell line SA1090 on DLP+ library A96213A

  Dataset EGAD00001009477

• Single Cell Genome Sequence for DLP+ library A98181A

  Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA919 passage 7, patient-derived xenograft SA1050A passage 1 on DLP+ library A98181A

  Dataset EGAD00001009479

• Single Cell Genome Sequence for DLP+ library A98240A

  Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA530 passage 3 on DLP+ library A98240A

  Dataset EGAD00001009480

• Tracking the evolution of esophageal squamous cell carcinoma under dynamic immune selection by multi-omics sequencing

  Intratumoral heterogeneity (ITH) has been linked to decreased efficacy of clinical treatments. However, although genomic ITH has been characterized in genetic, transcriptomic and epigenetic alterations are hallmarks of esophageal squamous cell carcinoma (ESCC), the extent to which these are heterogeneous in ESCC has not been explored in a unified framework. Further, the extent to which tumor-infiltrated T lymphocytes (TILs) are directed against cancer cells, but how the immune infiltration acts as a selective force to shape the clonal evolution of ESCC is unclear. In this study, we perform multi-omic sequencing on 186 samples from 36 primary ESCC patients. Through multi-omics analyses, it is discovered that genomic, epigenomic, and transcriptomic ITH are underpinned by ongoing chromosomal instability. Based on the RNA-seq data, we observe diverse levels of immune infiltrate across different tumor sites from the same tumor. We reveal genetic mechanisms of neoantigen evasion under distinct selection pressure from the diverse immune microenvironment. Overall, our work offers an avenue of dissecting the complex contribution of the multi-omics level to the ITH in ESCC and thereby enhances the development of clinical therapy.

  Dataset EGAD00001009482

• Single Cell Genome Sequence for DLP+ library A95621B

  Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA501 passage 2 on DLP+ library A95621B

  Dataset EGAD00001009487

• CASCADE low-pass whole genome sequencing data

  Low-pass whole genome sequencing data (median coverage: 0.37X, range: 0.07X-5.8X) from diagnostic formalin-fixed paraffin-embedded tissue and fresh frozen postmortem tissues from ten organs and postmortem blood from patients who participated in the CASCADE rapid autopsy program and died of metastatic castration resistant prostate cancer. For samples CA27_11, CA34_10, CA35_5, CA35_6, CA36_3, CA36_11, CA63_13, CA63_34, CA76_4, CA76_11, CA79_4, CA83_14 and CA83_26, we subsampled (using `samtools view -s 0.01` after mapping) from respective high coverage data from "CASCADE tumour high-coverage whole genome sequencing data" dataset.

  Dataset EGAD00001009494

• CASCADE tumour transcriptome data

  RNA-Seq data from 20 fresh-frozen postmortem samples from three patients who participated in the CASCADE rapid autopsy program and died of metastatic castration resistant prostate cancer.

  Dataset EGAD00001009492

• CASCADE germline whole genome sequencing data

  High-coverage whole genome sequencing data (median coverage: 23.5X, range: 14.14X-32.62X)) from white blood cells of the patients from isolated buffy coat of the blood drawn postmortem from patients who participated in the CASCADE rapid autopsy program and died of metastatic castration resistant prostate cancer.

  Dataset EGAD00001009493

• Transcriptomic Profile of Colorectal Cancer Samples

  Samples encompass primary colorectal tumors or metastasis of 75 patients, collected by Medical Pathologists from surgically removed specimens. Tissues were embedded in optimal cutting temperature (OCT) medium, snapshot frozen in liquid nitrogen within 40 minutes of collection and preserved at -80ºC. Samples were collected between June 2010 and October 2017 as part of a prospective biobanking project.

  Dataset EGAD00001009506

• Tumour sample for patient SA409

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA409

  Dataset EGAD00001009518

• Differential Presence of Exons in Cell-Free DNA

  Differential Presence of Exons in Cell-Free DNA Reveals Different Patterns in Colorectal Cancer Between Metastatic, Non-Metastatic Patients and Healthy Donors. 159 samples, Illumina sequencing technology.

  Dataset EGAD00001009510

• Single Cell Genome Sequence for DLP+ library A96141A

  Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA604 passage 8 on DLP+ library A96141A

  Dataset EGAD00001009513

• Tumour sample for patient SA597

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA597

  Dataset EGAD00001009521

• Normal sample for patient SA495

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA495

  Dataset EGAD00001009372

• Normal sample for patient SA425

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA425

  Dataset EGAD00001009371

• Normal sample for patient SA423

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA423

  Dataset EGAD00001009370

• Normal sample for patient SA300

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA300

  Dataset EGAD00001009369

• Normal sample for patient SA291

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA291

  Dataset EGAD00001009368

• Normal sample for patient SA289

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA289

  Dataset EGAD00001009367

• Normal sample for patient SA286

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA286

  Dataset EGAD00001009366

• Normal sample for patient SA280

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA280

  Dataset EGAD00001009365

• Normal sample for patient SA239

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA239

  Dataset EGAD00001009364

• Normal sample for patient SA679

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA679

  Dataset EGAD00001009379

• Normal sample for patient SA680

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA680

  Dataset EGAD00001009380

• Normal sample for patient SA681

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA681

  Dataset EGAD00001009381

• Normal sample for patient SA682

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA682

  Dataset EGAD00001009382

• Normal sample for patient SA683

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA683

  Dataset EGAD00001009383

• Normal sample for patient SA678

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA678

  Dataset EGAD00001009378

• Normal sample for patient SA677

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA677

  Dataset EGAD00001009377

• Normal sample for patient SA673

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA673

  Dataset EGAD00001009373

• Normal sample for patient SA676

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA676

  Dataset EGAD00001009376

• Normal sample for patient SA674

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA674

  Dataset EGAD00001009374

• Normal sample for patient SA675

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA675

  Dataset EGAD00001009375

• Paired ONT and downsampled Illumina cfDNA dataset

  The dataset contains 12 lung cancer plasma cfDNA samples, 8 bladder cancer and 2 healthy control urine cfDNA samples collected in EDTA collection tubes. Shallow WGS was performed using both Oxford Nanopore Technologies' MinION platform with an R9.4.1 flow cell and the SQK-PBK004 kit (22 files) and Illumina Novaseq platform with an S4 flow cell in PE150bp configuration (2x22 files).

  Dataset EGAD00001009392

• Targeted DNA sequencing dataset for the study "Molecular profiling of EBV associated diffuse large B-cell lymphoma"

  We performed deep targeted DNA sequencing with a panel of 74 selected cancer-related genes previously identified to be recurrently mutated in EBV associated DLBCL. Sequencing was performed on a HiSeq platform (Illumina) with 250 bp paired-end reads. There are 68 FFPE samples in this targetedDNAseq-dataset with 46 unpaired tumors and 22 normals used as a panel of normals.

  Dataset EGAD00001009396

• Whole-genome sequencing of high-grade serous ovarian cancer (HGSC) tumours and matched normals from long-term survivors.

  Whole-genome sequencing of high-grade serous ovarian cancer (HGSC) tumours and matched normals from long-term survivors performed as part of the Multidisciplinary Ovarian Cancer Outcomes Group (MOCOG) study. The dataset includes fastq files from 58 HGSC tumours (53 primary tumours and 5 recurrent tumours) and 53 matched normals from 53 long-term survivor patients. Sequence libraries were generated from tumour and matched normal genomic DNA using the KAPA HyperPrep PCR-free library preparation kit (Roche) according to manufacturer’s instructions. Sequencing was carried out by the Kinghorn Centre for Clinical Genomics Sequencing Laboratory (Sydney, Australia) on the HiSeq X Ten System (Illumina) to a minimum base coverage of 30-fold for normal DNA and 60-fold for tumour DNA samples.

  Dataset EGAD00001009398

• Strand-seq of hematopoietic stem and progenitor cells along human aging

  Somatic mosaicism (SM), referring to the presence of somatic mutations in sub-populations of cells within healthy individuals, is associated with an increased risk of a variety of diseases, including cancer. Blood is at particularly high risk of SM, given its rapid turnover and functionally- heterogeneous cell-type composition. While the roles of point mutations and large-scale rearrangements in blood SM have been scrutinised in recent years, the functional impact of mosaic structural variants (mSVs) remains poorly understood. Using haplotype-resolved single-cell multi-omics based on Strand-seq technology, we explored the mSV landscape of human hematopoietic stem and progenitor cells (HSPCs).

  Dataset EGAD00001009402

• Genome-wide 5-mC profiling in plasma of metastatic ALK-rearranged non-small cell lung cancer (NSCLC) patients receiving tyrosine kinase inhibitor therapy.

  Longitudinal plasma samples (n = 79) of 21 ALK-positive NSCLC patients and 13 healthy donors were collected alongside 15 ALK-positive tumor tissue and 10 healthy lung tissue specimens. All plasma and tissue samples were analyzed by cell-free DNA methylation immunoprecipitation sequencing to generate genome-wide 5-mC profiles. Paired cfMeDIP on NextSeq 550 using KAPA Hyper Prep Kit was done.

  Dataset EGAD00001009412

• Normal sample for patient SA997

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA997

  Dataset EGAD00001009573

• Normal sample for patient SA998

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA998

  Dataset EGAD00001009574

• Tumour sample for patient SA416

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA416

  Dataset EGAD00001009575

• Normal sample for patient SA597

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA597

  Dataset EGAD00001009572

• Normal sample for patient SA095

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA095

  Dataset EGAD00001009600